NICE rejects cancer drug for NHS

By Admin
The National Institute for Health and Clinical Excellence (NICE) has rejected plans for everolimus to be made available on the NHS. NICE ruled that th...

The National Institute for Health and Clinical Excellence (NICE) has rejected plans for everolimus to be made available on the NHS.

NICE ruled that the drug, which was proven to help prolong the life of kidney cancer patients, was too expensive.

Two other drugs, sunitinib and pazopanib, have been approved for use by the NHS. However, everolimus, which is also known as Afinitor and Novartis, has shown to increase overall survival rates where the other two had failed.

In justifying the decision not to recommend the drug for NHS use, NICE said it “does not provide enough benefit to patients to justify its high cost.”

To read the latest edition of Exec Digital, click here
New pill developed to treat MS

Flu virus samples to be shared globally

Faulty genes linked to ADHD

They did however accept that despite the research into the effect of the drug on survival times being inconclusive, the “overall survival gain would be likely to be more than three months”.

The charity Kidney Cancer UK is advising doctors and patients seeking the drug to ask for help from the government’s cancer drug fund, which is used for medication which has not available on the NHS.

Talking about the decision not to make everolimus available on the NHS, Dr Pat Hanlon, from Kidney Cancer UK, said his reaction was “one of deep disappointment.”

He added: “We know the NHS cannot afford all drugs, but they are effectively robbing people of a few months of life.”

The drug, which would have cost more than £200,000 for a full course of treatment, is used for second-line treatment of renal cell carcinoma, an advanced type of kidney cancer.

Approximately 4,000 people are diagnosed with that particular advanced type of cancer every year.

The chief executive of NICE, Sir Andrew Dillon, said: “We regret not to be able to recommend this drug, but we have to ensure that the money available to the NHS, for treating cancer and other conditions is used to best effect, particularly when the NHS, like the rest of the public sector, is under considerable financial pressure.”


Featured Articles

Johnson & Johnson: Turning supplier spend into local support

Johnson & Johnson’s Global Supplier Diversity & Inclusion team is growing spending with social enterprises around the globe to expand its impact

Seasonal Affective Disorder’s impact on health & solutions

Dr Ravi Gill & Dr. Naomi Newman-Beinart discuss Seasonal Affective Disorder and its treatments, from vitamin D spray to light therapy

CGI teams up with Totalmobile for digital healthcare service

CGI is driving efficiency in healthcare. Hear from Helena Jochberger, at Manufacturing Digital LIVE, a free virtual event on Wednesday 6th December 2023

Deloitte: generative AI can improve access to healthcare

Technology & AI

Wipro & NVIDIA’s revolutionary healthcare uses generative AI


Healthtech platform CoverSelf extends seed round to US$8.2m

Technology & AI